SCHEMBL5367481

SCHEMBL5367481

C=Cc1ccc(C[C@](CC)(OCC)C(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.41
PPARG P37231 4/20 0.41
THRB P10828 4/20 0.35
MAPT P10636 1/20 0.35
THRA P10827 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
PPARD Q03181 2/20 0.34
ALDH1A1 P00352 3/20 0.33
LMNA P02545 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
MCL1 Q07820 1/20 0.32
PSMD14 O00487 1/20 0.32
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963055 0.82 BLM (0.50) PPARAPPARGPPARDALDH1A1LMNA
SCHEMBL5197222 0.82 BLM (0.50) PPARAPPARGPPARDALDH1A1LMNA
SCHEMBL5365631 0.81 PPARA (0.49) PPARAPPARGPPARDALDH1A1LMNA
SCHEMBL4451916 0.77 PPARA (0.46) PPARAPPARGMAPTPPARDALDH1A1
SCHEMBL6396442 0.75 PPARA (0.48) PPARAPPARGPPARDALDH1A1LMNA
SCHEMBL7777170 0.74 LMNA (0.47) PPARAPPARGPPARDALDH1A1LMNA
SCHEMBL6387462 0.74 LMNA (0.47) PPARAPPARGPPARDALDH1A1LMNA
SCHEMBL8679105 0.72 ALDH1A1 (0.38) THRBTHRAALDH1A1
SCHEMBL3729766 0.71 SMN1; SMN2 (0.44) PPARAPPARGMAPTPPARDALDH1A1
SCHEMBL5142183 0.71 THRA (0.46) PPARAPPARGTHRBMAPTTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7309720-B2 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders ASTRAZENECA AB (SE) 2007-12-18 US disclosed
US-20060178432-A1 2-Ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders ASTRAZENECA AB (SE) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178432-A1 2-Ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders LIPC, PNLIP, CPT1A PPARA 34/4885PPARG 72/4885THRB 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.